Survival Rates Improve with SELLAS's New Treatment for Severe Lung Cancer, Phase 1 Study Shows

SELLAS Life Sciences Group Inc SLS released topline data from a Phase 1 trial of its lead clinical candidate, galinpepimut-S (GPS), combined with Bristol Myers Squibb Co BMY nivolumab (Opdivo) in patients with malignant pleural mesothelioma (MPM) who were either refractory to or relapsed after at least one line of the standard of care therapy.

Pleural mesothelioma (a lining that protects internal organs) is cancer that forms in the tissues covering the lungs and chest wall.

Nine of the ten patients enrolled received at least three doses of GPS, with the third GPS dose given in combination with nivolumab. Additional immune response data from all ten patients is expected by Q4 2023.

70.3 weeks (17.6 months) median overall survival (OS) in patients who received the combination therapy (9/10 patients) and 54.1 weeks (13.5 months) for all ten patients (nine patients with combination therapy and one GPS-only patient). 

Median overall survival for patients who entered the study as Stage IV patients was 62.3 weeks (15.6 months).

11.9 weeks median progression-free survival (PFS) for all patients.

30% disease control rate (DCR) with three patients achieving stable disease with a tumor volume decrease of up to 17%. 

No dose-limiting toxicities were observed.

Price Action: SLS shares are down 1.22% at $1.62 on the last check Wednesday.